Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

A CareSouth Carolina patient is among the first in the United States to receive a groundbreaking treatment aimed at slowing ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug ...

A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...

Kisunla (donanemab-azbt) is a prescription drug used to treat Alzheimer’s disease. The drug is given as an intravenous (IV) infusion by a healthcare professional. You’ll typically receive a ...